# reload+after+2024-01-21 11:44:12.814541
address1§2929 7th Street
address2§Suite 105
city§Berkeley
state§CA
zip§94710
country§United States
phone§510 982 6030
website§https://cariboubio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
fullTimeEmployees§137
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Rachel E. Haurwitz Ph.D.', 'age': 37, 'title': 'Co-Founder, CEO, President & Director', 'yearBorn': 1986, 'fiscalYear': 2022, 'totalPay': 833468, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ruhi A. Khan M.B.A.', 'age': 48, 'title': 'Chief Business Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 573900, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. Jason V. O'Byrne M.B.A.", 'age': 54, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 586355, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel  Poon', 'title': 'Vice President of Operations & Information Technology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Justin  Skoble', 'title': 'Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven B. Kanner Ph.D.', 'age': 64, 'title': 'Chief Scientific Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 500509, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amy  Figueroa C.F.A.', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Barbara G. McClung Esq., J.D.', 'age': 68, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 608382, 'exercisedValue': 0, 'unexercisedValue': 94128}, {'maxAge': 1, 'name': 'Ms. Reigin  Zawadzki', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  Fischesser', 'title': 'Vice President of Finance & Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§5
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.493
priceToSalesTrailing12Months§12.315101
currency§USD
dateShortInterest§1702598400
forwardEps§-1.73
pegRatio§0.35
exchange§NMS
quoteType§EQUITY
shortName§Caribou Biosciences, Inc.
longName§Caribou Biosciences, Inc.
firstTradeDateEpochUtc§1627047000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f11f6be1-a9a3-3c9c-bdb1-a1f42c197bdb
gmtOffSetMilliseconds§-18000000
targetHighPrice§30.0
targetLowPrice§13.0
targetMeanPrice§22.25
targetMedianPrice§23.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§13.984
grossMargins§-2.07798
ebitdaMargins§0.0
trailingPegRatio§None
